Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could ritalin help kids with sickle cell disease? new pilot trial launches

NCT ID NCT07226219

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 4 times

Summary

This pilot study at St. Jude Children's Research Hospital is testing whether a daily dose of extended-release methylphenidate (Ritalin) can safely improve attention, thinking, and school performance in children aged 8 to 17 with sickle cell disease. The trial will enroll 72 participants and focus on whether families can stick with the treatment for 4 weeks, while also tracking any side effects and changes in behavior. It is an early-stage study, so the main goal is to see if this approach is feasible and acceptable, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Methylphenidate (extended-release Ritalin)
What this could lead to
If it works, this could point toward a safe way to help children with sickle cell disease focus better at school and home.
What could go wrong
This is a very early, small pilot study focused on feasibility, not proof of effectiveness. Side effects of stimulants like methylphenidate may include appetite loss, sleep problems, or mood changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

8 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with SCD * Enrolled on the institutional protocol: Sickle Cell Clinical Research Intervention Program (SCCRIP) * Between the ages of 8.0 and 17.9 years \*Included if performance measure, rating scale or diagnostic criteria met (within the past 2 years): * \*Score at or below a Standard Score of 85 (16th percentile) on any 2 out of 4 performance measures: * NIH Toolbox Flanker * NIH Toolbox List Sorting * NIH Toolbox Dimensional Change Card Sort Test (DCST) * Wechsler Intelligence Scale for Children (WISC) -5/ Wechsler Adult Intelligence Scale (WAIS)-4 Digit Span Forward (DSF) * \*Score at or above a T Score of 60 (84th percentile) on any 1 out of 2 parent rating scales: * BRIEF-2 Global Executive * BASC-3 Attention * \*Have a documented diagnosis of attention deficit / hyperactivity disorder (any subtype) * English as the primary language * Research participant and one caregiver willing to participate and provide consent/assent according to institutional guidelines * Negative pregnancy test in female participant of childbearing age Exclusion Criteria: * Primary language other than English * Score below the 2nd percentile on the Wechsler Abbreviated Scale of Intelligence (WASI)-2 intelligence quotient (IQ) test (ever) * Uncontrolled seizures (seizure within the past 6 months) * Cardiomyopathy or known congenital structural cardiac defects * Stenotic valvular disease, left coronary artery stenosis, or history of myocarditis or pericarditis * History of heart arrhythmia including ventricular tachycardia, ventricular fibrillation, supraventricular tachycardia, QT prolongation or concomitant use of medications associated with QT prolongation * Two or more prior episodes of priapism * Blood pressure \>95th percentile at the three most recent visits consecutively (i.e., \>95th percentile reading at all three of the most recent hospital visits to St. Jude). * If blood pressure is \> 95th %ile compared to age-norms on the day of the baseline visit, a repeat blood-pressure reading will be performed both electronically and manually to confirm findings. * Stimulant medication within the past two weeks * Severe sensory loss * Previous adverse reaction to methylphenidate * Inability or unwillingness of research participant or legal guardian/representative to give written informed consent. * Currently prescribed another investigational medication. * Diagnosed with sickle cell-hereditary persistence of fetal hemoglobin (HbSHPFH), sickle cell homozygous C (CC), Hb S/N-Baltimore, or other rare genotypes that would preclude the participant from having the classic symptoms of sickle cell disease * Currently prescribed any of the following: * Phenobarbital (anticonvulsant) * Phenytoin (anticonvulsant) * Primidone (anticonvulsant) * Warfarin (anticoagulant) * Antipsychotic medications * Selective Serotonin Reuptake Inhibitor (SSRI) medications * Tricyclic antidepressant (TCA) medications * Vasopressor medications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Attention-deficit/hyperactivity disorder (ADHD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • St. Jude Children's Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.